Volume 26, Number 4—April 2020
Research Letter
Knowledge of Infectious Disease Specialists Regarding Aspergillosis Complicating Influenza, United States
Mitsuru Toda
, Susan E. Beekmann, Philip M. Polgreen, Tom M. Chiller, Brendan R. Jackson, and Karlyn D. Beer
, Susan E. Beekmann, Philip M. Polgreen, Tom M. Chiller, Brendan R. Jackson, and Karlyn D. Beer
Table
Summary results of survey on invasive pulmonary aspergillosis accompanying severe influenza among a network of infectious disease specialists, United States, May–June, 2018*
| Survey characteristic | No. (%) |
|---|---|
| Region where respondents are from, n = 114 | |
| Midwest | 25 (22) |
| Northeast | 27 (24) |
| South | 33 (29) |
| West |
29 (25) |
| Familiar with reports of aspergillosis after severe influenza infection, n = 114 | |
| Yes, familiar with reports | 29 (26) |
| No, not familiar with reports |
83 (73) |
| Seen or heard about a case of aspergillosis in the setting of severe influenza at place of work, n = 114 | |
| Yes, 1 case | 15 (13) |
| Yes, >2 cases | 6 (5) |
| No |
93 (82) |
| For patients with influenza requiring ICU admission, how commonly are lower respiratory specimens (e.g., bronchoalveolar lavage, bronchial wash) obtained, n = 108 | |
| Never | 2 (2) |
| Rarely | 28 (26) |
| Sometimes | 45 (42) |
| Very often | 28 (26) |
| Always |
5 (5) |
| When treating patients with severe influenza in the ICU and worsening respiratory function, how often do you order galactomannan testing (e.g., in serum or bronchoalveolar lavage), n = 107 | |
| Never | 30 (28) |
| Rarely | 45 (42) |
| Sometimes | 24 (22) |
| Very often | 4 (4) |
| Always | 4 (4) |
*n values indicate number of participants who responded. ICU, intensive care unit.
Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.